Kelly Brady's most recent trade in Seres Therapeutics Inc was a trade of 18,750 Stock Option (right to buy) done . Disclosure was reported to the exchange on July 8, 2026.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Seres Therapeutics Inc | Kelly Brady | See Remarks | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Jul 2026 | 18,750 | 18,750 | - | - | Stock Option (right to buy) | |
| Seres Therapeutics Inc | Kelly Brady | See Remarks | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 May 2026 | 180 | 8,621 (0%) | 0% | - | Common Stock | |
| Seres Therapeutics Inc | Kelly Brady | See Remarks | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 May 2026 | 91 | 639 | - | - | Restricted Stock Units | |
| Seres Therapeutics Inc | Kelly Brady | See Remarks | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 May 2026 | 89 | 269 | - | - | Restricted Stock Units | |
| Seres Therapeutics Inc | Kelly Brady | See Remarks | Sale of securities on an exchange or to another person at price $ 7.53 per share. | 15 May 2026 | 59 | 8,562 (0%) | 0% | 7.5 | 444 | Common Stock |
| Seres Therapeutics Inc | Kelly Brady | See Remarks | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Mar 2026 | 56,250 | 56,250 | - | - | Stock Option (right to buy) |